Research Press Releases

03.23.2018

Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers

03.11.2018

Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants

02.14.2018

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

02.12.2018

U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib

02.05.2018

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer

01.24.2018

Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®

01.19.2018

Survey of Ulcerative Colitis Patients and Gastroenterologists Indicates that Symptoms May Create a New Reality for Patients

01.08.2018

Pfizer Establishes New Partnering Model for Early-Stage Academic Research

01.03.2018

Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS